A new generation of oral direct anticoagulants Journal Article


Author: Soff, G. A.
Article Title: A new generation of oral direct anticoagulants
Abstract: After more than 50 years of thrombosis treatment and prophylaxis being based on heparin and vitamin K antagonists, a new generation of oral, direct anticoagulants is now available. The past 5 years have brought a strikingly large number of trials that evaluated these new oral anticoagulants in a range of clinical trials, particularly nonvalvular atrial fibrillation, thrombosis prophylaxis after major joint replacement surgery, treatment of venous thromboembolic events, and, most recently, acute coronary syndrome. These studies have been notably similar in design between the drugs for specific indication. This review focuses on the 3 drugs that either have recently been approved by the US Food and Drug Administration (dabigatran and rivaroxaban) or have the most mature phase III clinical data (apixaban). © 2012 American Heart Association, Inc.
Keywords: placebo; drug efficacy; drug safety; recommended drug dose; outcome assessment; deep vein thrombosis; high risk patient; pulmonary embolism; stroke; vein thrombosis; warfarin; heparin; anticoagulation; drug bioavailability; embolism; drug half life; risk reduction; heart atrium fibrillation; atrial fibrillation; brain hemorrhage; enoxaparin; fondaparinux; low molecular weight heparin; venous thromboembolism; apixaban; rivaroxaban; randomized controlled trial (topic); clinical trial (topic); subdural hematoma; acute coronary syndrome; dabigatran etexilate; thrombosis prevention; dabigatran; acenocoumarol; antivitamin k; nonvalvular atrial fibrillation
Journal Title: Arteriosclerosis Thrombosis and Vascular Biology
Volume: 32
Issue: 3
ISSN: 1079-5642
Publisher: Lippincott Williams & Wilkins  
Date Published: 2012-03-01
Start Page: 569
End Page: 574
Language: English
DOI: 10.1161/atvbaha.111.242834
PROVIDER: scopus
PUBMED: 22345595
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 2 April 2012" - "CODEN: ATVBF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gerald A Soff
    93 Soff